Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
1.66M
-
Shares change
-
-46.8K
-
Total reported value, excl. options
-
$11.1M
-
Value change
-
-$277K
-
Put/Call ratio
-
0.7
-
Number of buys
-
9
-
Number of sells
-
-11
-
Price
-
$6.68
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q1 2022
32 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.66M shares
of 107M outstanding shares and own 1.55% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (657K shares), BlackRock Inc. (253K shares), GEODE CAPITAL MANAGEMENT, LLC (137K shares), Equitable Holdings, Inc. (104K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (102K shares), AMERIPRISE FINANCIAL INC (96.7K shares), MORGAN STANLEY (91.3K shares), STATE STREET CORP (51.2K shares), PRELUDE CAPITAL MANAGEMENT, LLC (31.1K shares), and D. E. Shaw & Co., Inc. (22.1K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.